Ardsley Advisory Partners’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

Ardsley Advisory Partners’s Portfolio CORV Stock Details CORV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12,500	Closed	-$25K	–	209
2019 Q3	$25K	Hold	12,500	–	–	0.01%	131
2019 Q2	$27K	Buy	12,500 +2,134	+21%	+$5.45K	﹤0.01%	147
2019 Q1	$33K	Buy	+10,366	New	+$33.5K	0.01%	129
2017 Q4	–	Sell	-36,200	Closed	-$77K	–	183
2017 Q3	$77K	Sell	36,200 -3,800	-10%	-$12.9K	0.01%	129
2017 Q2	$180K	Hold	40,000	–	–	0.03%	130
2017 Q1	$120K	Buy	40,000 +11,100	+38%	+$32.7K	0.02%	146
2016 Q4	$80K	Hold	28,900	–	–	0.01%	121
2016 Q3	$90K	Hold	28,900	–	–	0.01%	150
2016 Q2	$148K	Buy	28,900 +5,000	+21%	+$24K	0.03%	138
2016 Q1	$98K	Buy	23,900 +500	+2%	+$2.67K	0.02%	135
2015 Q4	$190K	Hold	23,400	–	–	0.02%	131
2015 Q3	$197K	Hold	23,400	–	–	0.05%	132
2015 Q2	$220K	Buy	23,400 +8,400	+56%	+$78.3K	0.03%	142
2015 Q1	$139K	Buy	+15,000	New	+$144K	0.02%	176

Other funds holding CORV

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ardsley Advisory Partners's CORV Position: Q4 2019 in Review

Ardsley Advisory Partners sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q4 2019, closing a stake of 12,500 shares — an estimated $25K sold.

Ardsley Advisory Partners first reported a position in CORV in Q1 2015 and held it in 14 quarters. The position peaked at $220K in Q2 2015. 31 funds tracked by Wall St. Rank hold CORV as of Q4 2019.

Ardsley Advisory Partners reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q4 2019 after selling out during the quarter.
Ardsley Advisory Partners sold 12,500 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q4 2019, an estimated $25K.
Ardsley Advisory Partners first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q1 2015 and held it in 14 quarters.
Ardsley Advisory Partners's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $220K in Q2 2015.
31 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q4 2019.

Based on Ardsley Advisory Partners's 13F filing for Q4 2019, filed 14 Feb 2020.